Major Announcement: First HD patients treated with gene silencing drugs
GeM-HD identifies the first solid leads in the hunt for genetic variations that affect Huntington's disease onset
Variety in the HD gene’s on switch affects when symptoms arise.
Modified 'heavy hydrogen' form of tetrabenazine appears safe and effective for chorea in Huntington's disease
A clinical trial for an exciting therapy against HD is planned for 2015. The first step is to make sure it is safe.
CREST-E, a trial of the supplement creatine, has been stopped after an early analysis found it couldn't show benefit
Our third and final report on the 2014 European Huntington's Disease Network meeting in Barcelona
HDBuzz reports on the second day of science at the European HD Network meeting in Barcelona
Highlights from the opening day of the 2014 European Huntington's Disease network in Barcelona, Spain